|
|
SciBase's Nevisense (EIS) Included in the US NCCN Guidelines for Melanoma which supports the use of EIS in the detection of melanoma |
|
|
A new study demonstrates that Nevisense can predict atopic dermatitis in Newborns |
|
|
Recalculation of warrants of series TO 2 following rights issue and updated last day of trading in BTA from the rights issue |
|
|
SciBase announces final outcome of the rights issue and the resolution on a set-off issue within the framework of the offer to repurchase outstanding warrants of series TO 2 |
|
|
Change of date for publication of the year-end report for the financial year 2025 |
|
|
Increased commitment in SciBase rights issue |
|
|
SciBase publishes information document regarding rights issue |
|
|
SciBase announces outcome of the offer to repurchase outstanding warrants of series TO 2 |
|
|
The Board of Directors of SciBase resolves on a previously communicated rights issue of shares of approximately SEK 83 million |
|
|
SciBase Expands Its Intellectual Property Portfolio to include the analysis of the epithelial skin barrier with New European Patent |
